There are 412 resources available
Next steps for ADCs in managing brain metastases
Presenter: Rupert Bartsch
Session: New ADCs joining the field
Resources:
Slides
Webcast
Q&A and discussion
Session: New ADCs joining the field
Resources:
Webcast
Invited Discussant 182MO, 267MO and LBA3
Presenter: Peter A. Fasching
Session: Mini Oral session 1
Resources:
Slides
Webcast
183MO - Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): Second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial
Presenter: Hope Rugo
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
1MO - HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer
Presenter: Guillermo Villacampa Javierre
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
2MO - Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2- metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial
Presenter: Ana Mafalda Antunes De Melo e Oliveira
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 183MO, 1MO and 2MO
Presenter: Thomas Bachelot
Session: Mini Oral session 1
Resources:
Slides
Webcast
3MO - Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE
Presenter: Christine Desmedt
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
4MO - Neoadjuvant letrozole and palbociclib versus chemotherapy in the NeoPAL study: A translational analysis
Presenter: Paul Cottu
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 3MO and 4MO
Presenter: Cristina Saura Manich
Session: Mini Oral session 1
Resources:
Slides
Webcast